Nektar Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Nektar Therapeutics 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About NKTR

Nektar Therapeutics is a biotechnology company, which engages in the discovery and development of novel therapies which selectively modulate the immune system to treat autoimmune disorders. It also focuses on immunology and unparalleled expertise in polymer chemistry to create one-of-a-kind, highly-selective medicines with optimal therapeutic benefit. 

CEO
Howard W. Robin
CEOHoward W. Robin
Employees
63
Employees63
Headquarters
San Francisco, California
HeadquartersSan Francisco, California
Founded
1990
Founded1990
Employees
63
Employees63

NKTR Key Statistics

Market cap
2.40B
Market cap2.40B
Price-Earnings ratio
-8.44
Price-Earnings ratio-8.44
Dividend yield
Dividend yield
Average volume
1.71M
Average volume1.71M
High today
$71.20
High today$71.20
Low today
$64.97
Low today$64.97
Open price
$65.00
Open price$65.00
Volume
1.12M
Volume1.12M
52 Week high
$109.00
52 Week high$109.00
52 Week low
$21.02
52 Week low$21.02

Stock Snapshot

As of today, Nektar Therapeutics(NKTR) shares are valued at $71.17. The company's market cap stands at 2.4B, with a P/E ratio of -8.44.

On 2026-07-05, Nektar Therapeutics(NKTR) stock moved within a range of $64.97 to $71.20. With shares now at $71.17, the stock is trading +9.5% above its intraday low and -0.0% below the session's peak.

Trading volume for Nektar Therapeutics(NKTR) stock has reached 1.12M, versus its average volume of 1.71M.

The stock's 52-week range extends from a low of $21.02 to a high of $109.00.

The stock's 52-week range extends from a low of $21.02 to a high of $109.00.

NKTR News

Simply Wall St 45m
Nektar Therapeutics Advances Autoimmune Pipeline, Is The Upside Already Priced In?

Nektar Therapeutics (NKTR) is back in focus after positive mid stage data in alopecia areata and plans to start late stage trials in atopic dermatitis, raising...

Nektar Therapeutics Advances Autoimmune Pipeline, Is The Upside Already Priced In?
Investing.com 3d
Nektar Therapeutics R&D chief sells $397,670 of common stock - Investing.com

...

Nektar Therapeutics R&D chief sells $397,670 of common stock - Investing.com

Analyst ratings

90%

of 10 ratings
Buy
90%
Hold
10%
Sell
0%

People also own

Based on the portfolios of people who own NKTR. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.